UBS Group
UTMD icon

UBS Group’s Utah Medical Products UTMD Stock Holding History

UBS Group’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29M Buy
36,916
+36,602
+11,657% +$2.31M ﹤0.01% 4858
2025
Q4 		$17.6K Sell
314
-2,214
-88% -$128K ﹤0.01% 7874
2025
Q3 		$159K Sell
2,528
-565
-18% -$33.4K ﹤0.01% 6800
2025
Q2 		$176K Buy
3,093
+829
+37% +$45.1K ﹤0.01% 6806
2025
Q1 		$127K Sell
2,264
-697
-24% -$41.8K ﹤0.01% 6861
2024
Q4 		$182K Buy
2,961
+918
+45% +$59.3K ﹤0.01% 6508
2024
Q3 		$137K Buy
2,043
+72
+4% +$4.89K ﹤0.01% 6134
2024
Q2 		$132K Sell
1,971
-1,635
-45% -$111K ﹤0.01% 5974
2024
Q1 		$256K Sell
3,606
-1,252
-26% -$93.9K ﹤0.01% 5680
2023
Q4 		$409K Buy
4,858
+2,108
+77% +$175K ﹤0.01% 5249
2023
Q3 		$237K Sell
2,750
-5,262
-66% -$486K ﹤0.01% 5245
2023
Q2 		$747K Buy
8,012
+5,798
+262% +$546K ﹤0.01% 4495
2023
Q1 		$210K Buy
2,214
+624
+39% +$57.4K ﹤0.01% 5355
2022
Q4 		$160K Buy
+1,590
New +$145K ﹤0.01% 5664
2022
Q3 		– Sell
-391
Closed -$34K – 10961
2022
Q2 		$34K Sell
391
-153
-28% -$13.1K ﹤0.01% 6273
2022
Q1 		$49K Sell
544
-686
-56% -$63.1K ﹤0.01% 6525
2021
Q4 		$123K Buy
+1,230
New +$126K ﹤0.01% 6114
2021
Q2 		– Sell
-847
Closed -$73K – 9846
2021
Q1 		$73K Buy
847
+340
+67% +$29.9K ﹤0.01% 6202
2020
Q4 		$43K Sell
507
-73
-13% -$6.22K ﹤0.01% 6321
2020
Q3 		$46K Sell
580
-587
-50% -$48.7K ﹤0.01% 5716
2020
Q2 		$104K Sell
1,167
-9,049
-89% -$812K ﹤0.01% 5271
2020
Q1 		$961K Sell
10,216
-2,562
-20% -$238K ﹤0.01% 3385
2019
Q4 		$1.38M Buy
12,778
+1,812
+17% +$184K ﹤0.01% 3909
2019
Q3 		$1.05M Buy
10,966
+2,735
+33% +$254K ﹤0.01% 3926
2019
Q2 		$788K Buy
8,231
+1,031
+14% +$86.8K ﹤0.01% 3938
2019
Q1 		$635K Sell
7,200
-3,934
-35% -$346K ﹤0.01% 3900
2018
Q4 		$925K Buy
11,134
+3,041
+38% +$268K ﹤0.01% 3746
2018
Q3 		$762K Buy
8,093
+183
+2% +$17.5K ﹤0.01% 4085
2018
Q2 		$871K Sell
7,910
-373
-5% -$39K ﹤0.01% 3888
2018
Q1 		$819K Buy
8,283
+512
+7% +$45.7K ﹤0.01% 3873
2017
Q4 		$633K Sell
7,771
-653
-8% -$51K ﹤0.01% 4116
2017
Q3 		$620K Sell
8,424
-1,175
-12% -$84.5K ﹤0.01% 4051
2017
Q2 		$695K Buy
9,599
+1
+0% +$66 ﹤0.01% 3883
2017
Q1 		$597K Buy
9,598
+9,020
+1,561% +$568K ﹤0.01% 3921
2016
Q4 		$42K Buy
578
+119
+26% +$7.74K ﹤0.01% 5966
2016
Q3 		$27K Buy
459
+96
+26% +$6.11K ﹤0.01% 6037
2016
Q2 		$23K Buy
+363
New +$23.4K ﹤0.01% 6187
2015
Q3 		– Sell
-1,052
Closed -$63K – 8646
2015
Q2 		$63K Buy
1,052
+903
+606% +$50.8K ﹤0.01% 5805
2015
Q1 		$9K Sell
149
-563
-79% -$33.1K ﹤0.01% 7733
2014
Q4 		$43K Buy
+712
New +$39.4K ﹤0.01% 6683

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's UTMD Position: Q1 2026 in Review

UBS Group increased its Utah Medical Products (UTMD) stake by 11,657% in Q1 2026, buying an estimated $2.31M and bringing the position to 36,916 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4858.

UBS Group first reported a position in UTMD in Q4 2014 and has held it in 40 quarters since. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • UBS Group held 36,916 shares of Utah Medical Products worth $2.29M as of Q1 2026.
  • UBS Group bought 36,602 Utah Medical Products shares in Q1 2026, an estimated $2.31M.
  • Utah Medical Products made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4858 holding.
  • UBS Group first reported a position in Utah Medical Products in Q4 2014 and has held it in 40 quarters since.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.